Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Celldex Therapeutics stock
Learn how to easily invest in Celldex Therapeutics stock.
Celldex Therapeutics Inc is a biotechnology business based in the US. Celldex Therapeutics shares (CLDX) are listed on the NASDAQ and all prices are listed in US Dollars. Celldex Therapeutics employs 123 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Celldex Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CLDX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Celldex Therapeutics stock price (NASDAQ: CLDX)Use our graph to track the performance of CLDX stocks over time.
Celldex Therapeutics shares at a glance
|Latest market close||$30.32|
|52-week range||$15.37 - $57.20|
|50-day moving average||$39.43|
|200-day moving average||$39.25|
|Wall St. target price||$65.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.76|
Buy Celldex Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Celldex Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Celldex Therapeutics price performance over time
|1 week (2022-01-13)||0.66%|
|1 month (2021-12-20)||-22.49%|
|3 months (2021-10-16)||N/A|
|6 months (2021-07-20)||-30.22%|
|1 year (2021-01-20)||61.97%|
|2 years (2020-01-17)||1,137.55%|
|3 years (2019-01-18)||8,778.48%|
|5 years (2017-01-20)||789.15%|
Celldex Therapeutics financials
|Revenue TTM||$8.1 million|
|Gross profit TTM||$-35,116,000|
|Return on assets TTM||-10.27%|
|Return on equity TTM||-21.68%|
|Market capitalisation||$1.5 billion|
TTM: trailing 12 months
Celldex Therapeutics share dividends
We're not expecting Celldex Therapeutics to pay a dividend over the next 12 months.
Have Celldex Therapeutics's shares ever split?
Celldex Therapeutics's shares were split on a 1:15 basis on 10 February 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Celldex Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Celldex Therapeutics shares which in turn could have impacted Celldex Therapeutics's share price.
Celldex Therapeutics share price volatility
Over the last 12 months, Celldex Therapeutics's shares have ranged in value from as little as $15.37 up to $57.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celldex Therapeutics's is 2.7248. This would suggest that Celldex Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Celldex Therapeutics overview
Celldex Therapeutics, Inc. , a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University.
Celldex Therapeutics in the news
Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Frequently asked questionsWhat percentage of Celldex Therapeutics is owned by insiders or institutions?
Currently 4.525% of Celldex Therapeutics shares are held by insiders and 94.622% by institutions. How many people work for Celldex Therapeutics?
Latest data suggests 123 work at Celldex Therapeutics. When does the fiscal year end for Celldex Therapeutics?
Celldex Therapeutics's fiscal year ends in December. Where is Celldex Therapeutics based?
Celldex Therapeutics's address is: Perryville III Building, Hampton, NJ, United States, 08827 What is Celldex Therapeutics's ISIN number?
Celldex Therapeutics's international securities identification number is: US15117B2025 What is Celldex Therapeutics's CUSIP number?
Celldex Therapeutics's Committee on Uniform Securities Identification Procedures number is: 053491106
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
How to buy Specialty Building Products (SBP) stock when it goes public
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
How to buy HeartCore Enterprises (HTCR) stock when it goes public
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.
Ask an Expert